Overview
Natera's CEO, Steven Leonard Chapman, sold 5,970 shares of the company's stock across two days, generating approximately $1.4 million in proceeds. The transactions were recorded on January 27 and January 28 and were executed within a price range of $237.6624 to $240.5313 per share. The sales took place close to the stock's 52-week high of $256.36, at a time when the company's shares have risen roughly 64% over the prior six months.
Transaction details
- On January 27, Chapman sold 2,322 shares at $240.5313 per share. After that sale, his direct ownership was reported as 216,828 shares.
- On January 28, he sold an additional 3,648 shares at $237.6624 per share, reducing his direct holdings to 213,180 shares.
- The stock dispositions were carried out to satisfy tax liabilities associated with the vesting of Restricted Stock Units (RSUs) and were conducted pursuant to a pre-arranged 10b5-1 trading plan.
Company context and recent developments
Separately from the insider sales, Natera released preliminary fourth-quarter 2025 financials indicating expected revenue growth of nearly 40% year-over-year, a result the company says exceeded analyst expectations. Following the preliminary results, Canaccord Genuity maintained its Buy rating on the company.
Natera also reported progress on several clinical and product fronts. The company completed enrollment for the ACES-EMB trial, which is assessing the Prospera Heart test as a potential substitute for routine biopsies in monitoring heart transplant patients. In fetal genetic screening, Natera plans to present data from the EXPAND trial at the upcoming Society for Maternal-Fetal Medicine meeting; the data will highlight the company's Fetal Focus screening test.
In oncology, Natera introduced a new AI model intended to strengthen cancer recurrence risk assessments by integrating multiple data types to enhance the performance of its Signatera MRD test. The company is also collaborating with Exelixis on a phase 3 colorectal cancer trial that will use Signatera to help identify appropriate patients for the study. Natera characterized these items as part of its ongoing efforts to develop and expand its testing technologies across several medical domains.
What this means
The CEO sales were explicitly described as tax-covering transactions tied to RSU vesting and executed under a 10b5-1 plan. At the same time, the company is reporting strong preliminary revenue growth and multiple clinical and product milestones that span transplant monitoring, fetal screening, and oncology testing.